Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERITAS phase II trial in poor-response metastatic neuroblastoma
NL-OMON49491Phase 2Active, not recruiting
- Sponsor
- Gustave Roussy
- Start
- Feb 2020
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Iobenguane I-131, topotecan, thiotepa, temozolomide, irinotecan and 2 more in neuroblastoma (2 arms), sponsored by Gustave Roussy. Primary endpoint: 3-year event-free survival from randomization. Started Feb 2020; status: active, not recruiting.
02
Drugs
Iobenguane I-131topotecanthiotepatemozolomideirinotecan
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NL-OMON49491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49491.